Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
about
Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivationAND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphologyA mutation in CCDC50, a gene encoding an effector of epidermal growth factor-mediated cell signaling, causes progressive hearing lossThe emerging role of the LIV-1 subfamily of zinc transporters in breast cancerGenotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients17Beta-estradiol suppresses TLR3-induced cytokine and chemokine production in endometrial epithelial cells.Extracellular alkaline pH leads to increased metastatic potential of estrogen receptor silenced endocrine resistant breast cancer cellsFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerSTAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro.Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.Pathways to tamoxifen resistance.Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferationMathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.Markers of tumor-initiating cells predict chemoresistance in breast cancer.Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.Optimizing the use of neoadjuvant endocrine therapy.GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cellsP53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosisDNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.Anti-epidermal growth factor receptor drugs in cancer therapy.Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.ZD1839 (IRESSA): a selective EGFR-TK inhibitor.Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studiesSRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatmentNovel pharmacological approaches in the treatment of breast cancer.Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancerTherapeutic potential of tyrosine kinase inhibitors in breast cancer.Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivityHigh ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patientsInsulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.Treatment of HER2-positive metastatic breast cancer following initial progression.MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft ModelCancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses.Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors
P2860
Q21195230-8D3E5CCC-EFAB-4185-8A91-9509FF3264EDQ24654076-68B56510-16DA-42F0-92D5-DB15278C0B7BQ24670142-1CA4956A-34E1-43CB-AC81-55AD83F89B62Q24682854-3131861B-B369-4EDF-A48C-5E2D3A83EC30Q24810279-5A2CEFB3-B537-433A-936A-1856D81F59ECQ25256689-390B916E-D96A-41FD-B45E-133D791655E0Q27304731-0EA560F8-73DE-444E-8AF5-057ED28FE8ADQ28084982-BABB6E5D-0259-40F9-9495-21F5E31F7B01Q28481232-7F29ABA0-20CC-421E-A762-3C81D82E486EQ30420135-A997391B-2C85-4EC7-BFF4-CCFC732C7DC9Q30436239-5FD6CE99-F2A8-42A7-A15E-E8F35CC50C7CQ30441001-E911F1E3-3B51-4CD3-B93C-34740EBFBCD0Q33612070-0ACD31C4-007B-47C2-9C5A-F362E6C477C1Q33656026-3AE386F1-95CF-4BC0-80C1-A6F59BF0AAEEQ33781163-B4C1CCBF-E92A-48B3-9FDB-08205C171935Q33852622-9C44E413-2E6F-4984-9F75-3828843A9E4EQ33925038-2CD76749-D9B6-41DA-B360-006714BC6DE8Q33928138-699088CF-ACD6-42BD-9ECB-574D163C3882Q34207195-4B2D0BAA-3AA4-4640-8744-46DD6571A0A8Q34484781-720FC251-5B8B-4120-AD0D-6DB5D4E9732CQ34660837-25ED863E-A1CB-4656-B22F-0584F3868DFFQ34674316-2706497E-A067-4F66-84C6-6A0C86FBD92EQ34734513-A8155086-7760-4040-8DF0-1DE7272C4DEEQ34923304-D086B179-1E15-42C1-BE26-2A189CA279F5Q35016088-7F11E988-122D-418B-9E76-F1ED84C6589EQ35113027-F99EA3AD-7D82-4141-80EA-42C3394D31F0Q35143980-F15A0DD2-E37E-435B-978E-6D6BA9767B72Q35187806-6F9BD80C-E1A6-4843-970D-67B88924F564Q35356178-154F7FDB-29E2-4D4A-B780-D92939BF4B80Q35589209-EDAEDAB1-9E70-4F50-9C59-92D68D2DDFACQ35757179-2259D5EE-757A-4F3A-9CEC-9D5168BED879Q36051484-1377E8C1-C1B7-4C00-947E-3148CFD41E34Q36082594-BC0DE5AB-F202-4AD7-B087-C46A5124606AQ36090532-AB985E89-6B65-43F2-AEA2-8C8669797467Q36245528-5B664CEB-B8F9-408A-942C-E56CDFD3C786Q36263003-19AB0369-A00C-4EB8-B198-3C3325BA5E8BQ36275971-BDA5BBB6-15E1-4321-B785-2F6E7B1233DBQ36359541-58A4AD57-F102-4DC8-AA3D-B91027B8DD5EQ36372255-5AAC7336-DF01-4215-9FDE-8AB81EA5378CQ36420373-5261E077-54F5-4B5E-B6DA-9D9D666FCEBB
P2860
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Enhanced epidermal growth fact ...... trogen ICI 182,780 (Faslodex).
@en
Enhanced epidermal growth fact ...... trogen ICI 182,780 (Faslodex).
@nl
type
label
Enhanced epidermal growth fact ...... trogen ICI 182,780 (Faslodex).
@en
Enhanced epidermal growth fact ...... trogen ICI 182,780 (Faslodex).
@nl
prefLabel
Enhanced epidermal growth fact ...... trogen ICI 182,780 (Faslodex).
@en
Enhanced epidermal growth fact ...... trogen ICI 182,780 (Faslodex).
@nl
P2093
P356
P1433
P1476
Enhanced epidermal growth fact ...... trogen ICI 182,780 (Faslodex).
@en
P2093
C M Dutkowski
J M Knowlden
R A McClelland
R I Nicholson
T A Madden
P304
P356
10.1210/ENDO.142.7.8259
P407
P50
P577
2001-07-01T00:00:00Z